© 2001 European Society of Cardiology
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
Academic Unit of Cardiology, University of Hull, School of Medicine, Castle Hill Hospital Kingston Upon Hull, HU 16 5JQ, UK
* Corresponding author. Tel.: +44-1482-624087; fax: +44-1482-624085 E-mail address: j.g.cleland{at}medschool.hull.ac.uk (J.G. Cleland).
 |
Abstract |
|---|
This is a synopsis of presentations made at the American College of Cardiology (ACC) in 2001 summarising recent research developments relating to heart failure. Clinical studies of particular interest to physicians with an interest in heart failure and its prevention are reviewed. The COPERNICUS trial lends further support to the use of the beta-blocker, carvedilol, in severe heart failure and the CAPRICORN trial to its use in patients with post-infarction left ventricular systolic dysfunction. The MIRACLE study reinforces the evidence from three smaller trials that cardiac resynchronisation therapy is an effective treatment for the relief of symptoms in patients with severe heart failure and cardiac dyssynchrony. The STAF trial casts further doubt on the wisdom of cardioversion as a routine strategy for the management of chronic atrial fibrillation. The RITZ-2 trial suggests that an intravenous, non-selective endothelin antagonist is effective in improving haemodynamics and symptoms and possibly in reducing morbidity in severe heart failure. Observational studies in heart failure suggest that a moderate excess of body fat and elevated blood cholesterol may be desirable in patients with heart failure, challenging the current non-evidenced-based vogue for cholesterol lowering therapy in heart failure. The RENAISSANCE and RECOVER outcome studies of etanercept, a tumour necrosis factor (TNF) receptor analogue that blocks the effect of TNF, were stopped because of lack of evidence of benefit shortly after the ACC.
Key Words: Capricorn • Copernicus • Miracle • Staf • RITZ-2 • Recover • Renaissnace • Heart failure
Received March 28, 2001; Revised March 31, 2001; Accepted April 4, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials JAMA, November 7, 2007; 298(17): 2009 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Moro, M.-G. Jouan, A. Rakotovao, M.-C. Toufektsian, O. Ormezzano, N. Nagy, A. Tosaki, J. de Leiris, and F. Boucher Delayed expression of cytokines after reperfused myocardial infarction: possible trigger for cardiac dysfunction and ventricular remodeling Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3014 - H3019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rivera, R. Talens-Visconti, R. Sirera, V. Bertomeu, A. Salvador, R. Cortes, F. G. de Burgos, V. Climent, R. Paya, L. Martinez-Dolz, et al. Soluble TNF-{alpha} and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and relationship with plasma levels Eur J Heart Fail, December 1, 2004; 6(7): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Moe, J. Marin-Garcia, A. Konig, M. Goldenthal, X. Lu, and Q. Feng In vivo TNF-{alpha} inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1813 - H1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor Anemia as a risk factor and therapeutic target in heart failure J. Am. Coll. Cardiol., September 1, 2004; 44(5): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sekiguchi, X. Li, M. Coker, M. Flesch, P. M Barger, N. Sivasubramanian, and D. L Mann Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure Cardiovasc Res, August 15, 2004; 63(3): 433 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tavazzi, G. Tognoni, M. G. Franzosi, R. Latini, A. P. Maggioni, R. Marchioli, G. L. Nicolosi, M. Porcu, and on behalf of the GISSI-HF investigators Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure Eur J Heart Fail, August 1, 2004; 6(5): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Francis, Y. Chu, A. K. Johnson, R. M. Weiss, and R. B. Felder Acute myocardial infarction induces hypothalamic cytokine synthesis Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2264 - H2271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Fu, C.-S. Chi, S.-C. Yin, B. Hwang, Y.-T. Chiu, and S.-L. Hsu Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF{alpha}-caspase signaling pathway Cardiovasc Res, June 1, 2004; 62(3): 558 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Oyama, C. Blais Jr, X. Liu, M. Pu, L. Kobzik, R. A. Kelly, and T. Bourcier Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice Circulation, February 17, 2004; 109(6): 784 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Tovar and J. G Gums Tezosentan in the Treatment of Acute Heart Failure Ann. Pharmacother., December 1, 2003; 37(12): 1877 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rich and V. V. McLaughlin Endothelin Receptor Blockers in Cardiovascular Disease Circulation, November 4, 2003; 108(18): 2184 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. F. Cleland and A. L. Clark Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: Too many cooks will spoil the broth J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1234 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sorokin and D. E. Kohan Physiology and pathology of endothelin-1 in renal mesangium Am J Physiol Renal Physiol, October 1, 2003; 285(4): F579 - F589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Capucci and D. Aschieri Antiarrhythmic drug therapy: what is certain and what is to come Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H8 - H18. [Abstract] [PDF]
|
|
|
|
|
|
A. P. Coletta, A. L. Clark, A.-M. L. Seymour, and J. G.F. Cleland Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE Eur J Heart Fail, August 1, 2003; 5(4): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakamura, S. Umemoto, G. Naik, G. Moe, S. Takata, P. Liu, and M. Matsuzaki Induction of left ventricular remodeling and dysfunction in the recipient heart after donor heart myocardial infarction: new insights into the pathologic role of tumor necrosis factor-alpha from a novel heterotopic transplant-coronary ligation rat model J. Am. Coll. Cardiol., July 2, 2003; 42(1): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, N. Nikitin, A. Louis, and A. Clark Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans Eur J Heart Fail, June 1, 2003; 5(3): 391 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kwon, T. R. Cote, M. S. Cuffe, J. M. Kramer, and M M. Braun Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist Ann Intern Med, May 20, 2003; 138(10): 807 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. O'Connor, W. A. Gattis, K. F. Adams Jr, V. Hasselblad, B. Chandler, A. Frey, I. Kobrin, M. Rainisio, M. R. Shah, J. Teerlink, et al. Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4) J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1452 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Mehra, P. A. Uber, and G. S. Francis Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1606 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A.A. Fox, and D. E. Newby Intra-Arterial Tumor Necrosis Factor-{alpha} Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 695 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Felder, J. Francis, Z.-H. Zhang, S.-G. Wei, R. M. Weiss, and A. K. Johnson Heart failure and the brain: new perspectives Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R259 - R276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Francis, R. M. Weiss, A. K. Johnson, and R. B. Felder Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R328 - R335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen and W. H. van Gilst The pharmacological management of heart failure: too many treatments? Eur J Heart Fail, January 1, 2003; 5(1): 5 - 8. [Full Text] [PDF]
|
|
|
|
|
|
A.P. Coletta, N. Nikitin, A.L. Clark, and J.G.F. Cleland Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure Eur J Heart Fail, January 1, 2003; 5(1): 95 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sirera, A. Salvador, I. Roldan, R. Talens, A. Gonzalez-Molina, and M. Rivera Quantification of proinflammatory cytokines in the urine of congestive heart failure patients. Its relationship with plasma levels Eur J Heart Fail, January 1, 2003; 5(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Brehm, S. C. Wolf, S. Gorner, N. Buck-Muller, and T. Risler Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study Eur J Heart Fail, December 1, 2002; 4(6): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.B. Felix, A. Staudt, and G. Baumann Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I63 - I68. [Abstract] [PDF]
|
|
|
|
|
|
A.P. Coletta, A.A. Louis, A.L. Clark, N. Nikitin, and J.G.F. Cleland Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II Eur J Heart Fail, October 1, 2002; 4(5): 661 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vescovo, B. Ravara, V. Gobbo, M. Sandri, A. Angelini, M. Della Barbera, M. Dona, G. Peluso, M. Calvani, L. Mosconi, et al. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure Am J Physiol Cell Physiol, September 1, 2002; 283(3): C802 - C810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gras, C. Leclercq, A. S.L. Tang, C. Bucknall, H. O. Luttikhuis, and A. Kirstein-Pedersen Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study Eur J Heart Fail, June 1, 2002; 4(3): 311 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Coletta, S. Thackray, N. Nikitin, and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL Eur J Heart Fail, June 1, 2002; 4(3): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McMurray and M. A. Pfeffer New Therapeutic Options in Congestive Heart Failure: Part II Circulation, May 7, 2002; 105(18): 2223 - 2228. [Full Text] [PDF]
|
|
|
|
|
|
A. Yndestad, J. Kristian Damas, H. Geir Eiken, T. Holm, T. Haug, S. Simonsen, S. S. Froland, L. Gullestad, and P. Aukrust Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure Cardiovasc Res, April 1, 2002; 54(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Massie Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Louis, I. R. Manousos, A. P. Coletta, A. L. Clark, and J. G.F. Cleland Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH Eur J Heart Fail, January 1, 2002; 4(1): 111 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Cohn, G. Tognoni, and the Valsartan Heart Failure Trial Investigators A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1667 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Coletta and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology -- WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME Eur J Heart Fail, December 1, 2001; 3(6): 747 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thackray, A. Coletta, P. Jones, A. Dunn, A. L. Clark, and J. G.F. Cleland Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF Eur J Heart Fail, August 1, 2001; 3(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|